mRNA Ocular Delivery via Nanoparticle Barriers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for ocular diseases face challenges due to the unique anatomy and physiology of the eye, which pose barriers to effective drug delivery, including static and dynamic barriers that hinder the distribution of therapeutic agents.
Innovation Solution
The use of messenger RNA (mRNA) therapy for delivering therapeutic proteins directly to the eye through various administration routes, such as intravitreal, intracameral, subconjunctival, subtenon, retrobulbar, topical, and posterior juxtascleral administration, utilizing lipid or polymer-based nanoparticles to ensure effective protein expression and activity within the eye.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drug delivery methods are used for ocular diseases, then the treatment approach is simple and direct, but the static and dynamic barriers of the eye (anatomy and physiology) prevent effective drug distribution and protein expression
Solution Approach 1:
Lipid or polymer-based nanoparticles are used as intermediary carriers to deliver mRNA across the eye's static and dynamic barriers. These nanoparticles protect the mRNA from degradation, facilitate cellular uptake, and enable effective protein expression in ocular tissues despite the challenging anatomical and physiological barriers.
Solution Approach 2:
The invention changes the physical and chemical parameters of the therapeutic agent by using mRNA encapsulated in nanoparticles instead of conventional proteins or small molecules. This parameter change enables the therapeutic to overcome barriers that would otherwise prevent effective delivery and sustained expression in the eye.
2Productivity
If mRNA therapy is used to achieve robust protein expression in the eye, then effective treatment of ocular diseases is achieved, but the complexity of delivery through static and dynamic barriers increases
Solution Approach 1:
Nanoparticles serve as mediators that protect mRNA from enzymatic degradation in the ocular environment and facilitate its delivery to target cells. This intermediary approach enables robust protein expression while managing the complexity of delivering fragile mRNA molecules through the eye's barriers.
Solution Approach 2:
The lipid or polymer-based nanoparticle shells provide a flexible protective structure that encapsulates the mRNA, allowing it to navigate through the eye's static and dynamic barriers while maintaining structural integrity and enabling sustained protein expression.
3Adaptability or versatility
If multiple administration routes (intravitreal, intracameral, subconjunctival, etc.) are utilized for mRNA delivery, then effective treatment coverage is improved, but the complexity of administration procedures increases
Solution Approach 1:
The nanoparticle-mRNA formulation is designed with universal applicability across multiple administration routes (intravitreal, intracameral, subconjunctival, subtenon, retrobulbar, topical, and posterior juxtascleral). This multi-functional design allows the same therapeutic composition to be effectively delivered through different routes depending on the specific ocular condition and clinical requirements.
Data Source
AI summary
The present invention provides, among other things, a method of ocular delivery of messenger RNA (mRNA), comprising administering into an eye of a subject in need of delivery a composition comprising an mRNA encoding a protein, such that the administration of the composition results in expression of the protein encoded by the mRNA in the eye.